Use of the BRAF inhibitor vemurafenib (Zelboraf) combined with the anti-CD20 monoclonal antibody obinutuzumab (Gazyva) led to high rates of complete remission as frontline therapy for patients with ...
Adding tafasitamab and lenalidomide to rituximab, cyclophosphamide, hydroxydaunomycin, oncovin, and prednisone (R-CHOP) improves outcomes in newly diagnosed diffuse large B-cell lymphoma and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results